Who prescribes quetiapine in Denmark?
antipsychotics
off-label
prescriber
quetiapine
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
19
04
2022
received:
10
03
2022
accepted:
21
04
2022
pubmed:
11
5
2022
medline:
20
8
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
The second-generation antipsychotic quetiapine is commonly used off-label for its anxiolytic and hypnotic properties. However, quetiapine is associated with problematic side-effects. We used Danish Medicinal Product Statistics and a 20% random sample of the Danish population's prescription fills (2001-2020) to describe the utilization of quetiapine and proportion of various prescriber types (general practitioner [GP], specialist in private practice, hospital physician and other prescribers) both in connection to first-time and subsequent prescriptions. In 2020, 92% of all quetiapine was dispensed outside hospitals and the average daily dispensed quantity of quetiapine per user corresponded to 100 mg/user/d. A GP issued 53% of first-time prescriptions and 75% of subsequent prescriptions for quetiapine in 2020. The proportion of quetiapine prescriptions issued by GPs varied by age group-from 14% among 0-17-year-olds to 93% among the ≥80-year-olds. Future initiatives on the rational use of quetiapine and related drugs, especially among adults, should target GPs.
Identifiants
pubmed: 35535441
doi: 10.1111/bcp.15388
pmc: PMC9545446
doi:
Substances chimiques
Antipsychotic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4224-4229Informations de copyright
© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Subst Use Misuse. 2020;55(2):304-313
pubmed: 31573374
JAMA Intern Med. 2016 Sep 1;176(9):1390-1
pubmed: 27400391
Eur Neuropsychopharmacol. 2017 Oct;27(10):1064-1076
pubmed: 28755801
Int J Epidemiol. 2017 Jun 1;46(3):798-798f
pubmed: 27789670
Expert Opin Investig Drugs. 2010 Oct;19(10):1187-204
pubmed: 20795889
Epidemiol Psychiatr Sci. 2021 Apr 06;30:e28
pubmed: 33820580
Br J Clin Pharmacol. 2021 Jul;87(7):2982-2987
pubmed: 33496033
Int J Epidemiol. 2016 Oct;45(5):1401-1402g
pubmed: 27892409
Pharmacol Rev. 2018 Apr;70(2):197-245
pubmed: 29487083
CMAJ Open. 2018 Apr 30;6(2):E191-E196
pubmed: 29712643
Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156
pubmed: 34529832
Br J Clin Pharmacol. 2022 Sep;88(9):4224-4229
pubmed: 35535441
Br J Clin Pharmacol. 2020 Dec;86(12):2435-2440
pubmed: 32374500
Br J Clin Pharmacol. 2019 Jul;85(7):1598-1606
pubmed: 30927284
Ther Clin Risk Manag. 2017 Jun 29;13:757-777
pubmed: 28721057
Eur J Clin Pharmacol. 2017 Sep;73(9):1173-1179
pubmed: 28623386
Br J Clin Pharmacol. 2020 Jul;86(7):1444-1445
pubmed: 32100324
Basic Clin Pharmacol Toxicol. 2016 Oct;119(4):376-80
pubmed: 27098169
JAMA Netw Open. 2021 May 3;4(5):e213209
pubmed: 33961038